CPHI is an important meeting for all customers and suppliers. The exhibition has covered 15 segments related to the entire pharmaceutical industry chain. We Jinan Million did not have stall this year. Yet we went and learned a lot. In recent years, China’s pharmaceutical source innovation force has been rising continuously. Many advanced companies in each related field like pharmaceutical raw materials, intermediates and fine chemicals, preparations, pharmaceutical excipients, natural extracts, contract customization, biopharmaceuticals, pharmaceutical machinery, packaging materials, laboratory instruments, environmental protection and cleaning, and so on have joined CPHI Shanghai China with their top products and stronger international market competitiveness.

Many new pharmaceutical products are researched for better health. Like Elacestrant dihydrochloride also called RAD1901 dihydrochloride Cas 1349723-93-8, purity is 99% treats breast cancer. Ritlecitinib is for alopecia areata approved by FDA in June,  2023. Our tech team is working hard to find a new route of synthesis for Ritlecitinib or Ritlecitinib tosylate. As been told, after the success of r&d, our product cost will be much much lower than other Ritlecitinib manufacturers. Can’t wait to see the large production of it.